Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: J Immunol. 2015 Apr 27;194(11):5472–5487. doi: 10.4049/jimmunol.1401343

Figure 7. PGE2-induced NLRP3 inflammasome inhibition requires higher doses in CAPS patients.

Figure 7

(A) PBMCs from four healthy subjects were treated with LPS (1 μg/ml) for 3 h in complete medium, followed by treatment with the indicated doses of PGE2 or vehicle (EtOH) and ATP (2 mM) or alum (400 μg/ml) for 30 min in serum-free medium. Supernatants and lysates were collected for WB. (B) PBMCs from five CAPS patients with designated mutations in NLRP3 were treated with LPS (1 μg/ml) for 3 h in complete medium, followed by treatment with indicated doses of PGE2 or vehicle (EtOH) for 30 min in serum-free medium. Supernatants and lysates were collected for WB.